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Abstract 
Background: Atrial fibrillation (AF) is the most prevalent arrhythmia in the clinical practice, and a range of 
cardiovascular disease (CVD) is associated with the increased risk of AF. While many epidemiological studies identified 
risk factors for AF in general population, there have been few studies investigating the prevalence of and risk factors for 
paroxysmal AF (Paf) in patients with CVD. In this study, we examined the prevalence of Paf and attempted to define the 
risk factors for Paf in patients with CVD but no known history of AF.  Study Design and setting: We selected 342 
patients who had prior CVD, or were at risk for CVD, but had not been diagnosed with AF. All patients were followed up 
with specified tests (e.g., blood tests and urinalysis) at our outpatient clinic. To detect Paf in these patients, a 24-hour 
Holter electrocardiography (ECG) was performed.  Results: Paf was detected in 25 patients (7.2 %) in 342 enrolled 
patients (mean age, 67.0 years; men, 42.2%). Comparison of clinical features showed that patients with Paf were older 
(p=0.02), had higher serum brain natriuretic peptide (p=0.04) than those without Paf. More patients with Paf had a 
history of heart failure (HF) (56.0 % vs.15.7%; odds ratio [OR], 6.81; 95% confidential interval [CI] 2.93 to 15.9; 
p<0.0001) and proteinuria (32.0% vs. 15.1%; OR 2.64;95%CI 1.08 to 6.45; p=0.03) as well as with advancing age (OR 
1.03; 95%CI 1.00 to 1.06; p=0.03). Multivariate logistic regression analysis revealed that HF was significantly associated 
with Paf independently of other comorbidities (OR 5.40; 95%CI 2.07 to 14.1; p=0.0006). Conclusion: Our study using 24-
hour Holter ECG readily identified Paf in the patients with CVD but without diagnosed AF. HF was most strongly 
associated with Paf independently of other risk factors established by prior population-based studies. A history of HF 
should be considered as a leading risk factor for Paf in clinical practice. 




Atrial fibrillation (AF) is the most common arrhythmia that increases the risk of morbidity and mortality [1-
4]. Clinical outcomes of AF is determined by a combination of hemodynamic alteration, progressive atrial 
structural and autonomic remodeling, impaired atrial-ventricular contractile interaction, ischemic stroke, 
and systemic thromboembolism[5]. Over the past decades, several prospective cohort studies revealed the 
individuals with nonvalvular AF, the most common form of AF, is associated with 5-fold increase in the risk 
for stroke, a 2-fold increase in the risk for allcause mortality, and a 3-fold increase in the risk for heart 
failure (HF), and therefore AF poses a major public health problem[ 2, 6, 7].   
 
While AF may occur in the absence of known structural or electrophysiological abnormalities, many 
population studies have identified various risk factors associated with AF. Long-established risk factors for 
AF include advancing age, male sex, a history of myocardial infarction, heart failure (HF), hypertension, 
diabetes, and chronic kidney disease (CKD) [5, 8-12]. Therefore, the high prevalence of AF in the patients 
with any types of cardiovascular disease (CVD) should always be considered in everyday clinical practice. 
However, AF is often transient, asymptomatic and consequently undiagnosed even in the patients with 
established CVD who regularly visit outpatient department and undertake routine ECG at the follow-up of 
their disease. 
 
Prevailing notion about natural history of AF is that AF begins with paroxysmal episodes that increase in 
frequency and duration, then progress to more persistent AF subtypes [13 14-16]. Therefore, the 
understanding the risk factors for Paf may help us to detect AF onset before the progression to persistent 
AF in clinical practice. In contrast to the increasing number of population-based studies which identified 
the association of persistent or permanent AF with clinical risk factors, there have been few studies which 




Since Paf is likely to be asymptomatic in patients with a variety of 
comorbidities including advancing age, the prevalence of Paf is often 
underestimated in the patients with CVD [18].   
 
In this study, we aimed to determine the prevalence of Paf by utilizing 
24-hour Holter ECG and to define the risk factors associated with Paf in 
the patients who had prior cardiovascular disease (CVD), or were at risk 
for CVD but not being diagnosed with AF on routine standard 12-lead  
ECG during follow-up. We found that 24-hour Holter ECG can often 
identify Paf in patients with CVD, and that among many established risk 






All patients gave written informed consent, and the Institutional 
Review Board of the Kan-etsu Chuo Hospital approved the study 
protocol.  
 
Data collection  
 
From January 2014 to November 2016, we performed 24-hour Holter 
ECG in 349 patients with cardiovascular disease but not known AF, who 
regularly visit outpatients department. Participants are eligible for 
inclusion if 16 years or older and previously diagnosed as having at 
least one of the following conditions: HF, myocardial infarction, 
valvular disease, cardiomyopathy, hypertension, diabetes mellitus, or 
previous stroke. Major exclusion criteria were acute myocardial 
infarction, current angina, current decompensated heart failure, 
accelerated hypertension, a history of AF, current oral anticoagulation 
treatment, active cancer, and other serious illness.   
 
Definition of paroxysmal atrial fibrillation  
 
All enrolled patients underwent 24-hour Holter ECG, and the presence  
or absence of Paf episodes was determined. In this study, Paf was 
defined as AF persisted 30 seconds or more and resolved within 7 days 
[6]. When an AF episode lasting ≥6 minutes was detected, oral 
anticoagulation was initiated.  
 
Risk factors  
 
All participants completed a questionnaire concerning demographic  
and medical history information. Blood was drawn to measure total 
cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triglyceride (TG), fasting glucose, 
hemoglobin A1c, and serum creatinine. Hypertension was defined as 
>140/90 mmHg or use of antihypertensive medication. Participants 
were considered to have type 2 diabetes if a fasting plasma glucose 
levels>126mg/dL, 2h post-loaded or casual glucose levels >200mg/dL, 
hemoglobin A1c >6.5%, or current use of oral hypoglycemic agents or 
insulin. Dyslipidemia was defined by LDL-C>140mg/dL, and/or HDL-
C<40mg/dL, and/or TG>150mg/dL, or current use of anti-
hyperlipidemic agents. Estimated glomerular filtration rate (eGFR) was 
calculated using MDRD study equation modified for Japanese 
population:194 x serum creatinine-1.09 x Age-0.287 x 0.739 (if female) [19]. 
Proteinuria was defined as a urine dipstick protein result of >+1.    
Clinical characteristics of patients with Paf were compared to those of 
patients without Paf to identify relevant risk factors. For comparison, 
all patients underwent physical examination, blood tests, and 
urinalysis.  
 
Statistical analysis   
 
The Paf prevalence was expressed as a percentage of the numbers. 
Continuous variables are expressed as mean+SD unless otherwise 
indicated. Categorical variables were summarized by count and 
percentage. Brain natriuretic peptide (BNP) values were log 
transformed to approach a normal distribution. Characteristics of the 
patients with Paf or not were compared using Student’s t test and the 
Mann-Whitney U test for continuous data and the chi-square test for 
categorical data.  
 
Univariate logistic regression analysis was performed on age, eGFR<60, 
proteinuria, and HF to calculate odds ratio (OR). Then, multivariate 
logistic regression analysis was performed on these risk factors in order 
to evaluate the strength of the association. Differences in the predicted 
values were determined by the area under the curve (AUC). The level 
of significance was 5% and all p values and confidence intervals were 2-
sided. All analyses were conducted using SPSS version 21.0 (SPSS, 




Clinical Characteristics   
 
Our study had 349 patients with cardiovascular disease including HF, 
coronary artery disease, valvular disease (excepting for mitral stenosis), 
hypertension, and cardiomyopathy, but without AF diagnosis. The 
patients with CKD at stage 5, and the patients receiving anticoagulation 
therapy were excluded. An overall mean age was 67.0 years, and 42.4% 
of the patients were men.  
 
In this cross-sectional study, Paf was detected in 25 (7.2%) of the 349 
patients by a single 24-hour Holter ECG examination. Table 1 provides 
the clinical characteristics of patients with and without Paf. Patients 
with Paf were more likely to be older (p=0.02), had more frequent 
history of HF (p<0.001), compared with patients without Paf. There 
were no difference in the prevalence of history of hypertension, angina 
pectoris, myocardial infarction, diabetes, CKD, and dyslipidemia 
between patients with and without Paf.  
 
Mean of log transformed BNP concentrations was higher (p=0.04) and 
mean eGFR was lower (p=0.02) in patients with Paf compared with 
those without Paf. Notably, patients with Paf were more likely to have 
proteinuria (p=0.03). Systolic blood pressure, glycosylated hemoglobin 
(HbA1c), prevalence of left ventricular hypertrophy as evaluated by 
ECG, and left ventricular ejection fraction were similar between two 
groups. There were no significant difference in the use of angiotensin 
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers 
(ARB), blockers and statins, but patients with Paf more often used 
calcium channel blockers (CCB) (p=0.04).    
 
Risk factors for Paf   
 
Among the cardiovascular risk factors listed in Table 1, advancing age,  
proteinuria, and a history of HF were significantly associated with Paf. 
Table 2 shows the univariate logistic regression analysis of odds ratios 
(ORs) for Paf and the respective p values. Age was highly associated 
with Paf (OR 1.03 per 1 year increase, 1.03; 95% confidence interval 
(CI) 1.00-1.06, p=0.03). HF was strongly related to Paf (OR 6.81;95% CI, 
2.93-15.9, p<0.0001). Patients with proteinuria were associated with 
2.64-fold increased risk for AF (95%CI 1.08-6.45, p=0.03). OR for eGFR 
<60mL/min/1.73m2 was 2.15, but did not reach statistical significance 
(p=0.08). These results are also shown in forest plots in Fig.1. No 
significant differences on ORs were observed between two groups for 
the other clinical features examined including male sex, body mass 
index (BMI),  LogBNP, HbA1c, left ventricular hypertrophy evaluated by 








Table 1. Comparison of clinical manifestations between Paf (+) and Paf (-) patients* 
 
  Total (n=349) Paf (+) (n=25) Paf (-) (n=324)  P 
Age - years  67.0 +18.3 74.9 +15.8 66.3 +18.4 0.02 
Male sex - no. (%) 148 (42.4) 11 (44.0) 137 (42.3) 0.43 
Height – cm  158.0 + 11.3 155.2 + 12.1 158.2+ 11.1 0.22 
Weight – kg  58.0 + 14.0 56.5 + 14.3 58.1 + 14.0 0.60 
Body mass index - kg/m2  23 + 4 23 + 5 23 + 4 0.66 
Systolic blood pressure – mmHg  127.5 + 19.4 131.5 + 15.5 127.2 + 19.7 0.30 
Diastolic blood pressure – mmHg  74.4 + 14.0 80.1 + 11.2 73.9 + 14.1 0.04 
Laboratory data  
   
 LogBNP  1.80 + 0.65 2.09 + 0.8 1.77 + 0.62 0.04 
 HbA1c - %  6.1+ 1.0 5.7 + 0.6 6.1 + 1.0 0.16 
eGFR - mL/min/1.73m2  61.8 + 20.0 52.6 + 21.6 62.5 + 19.4 (19.4) 0.02 
 eGFR<60 mL/min/1.73m2  - no. (%) 152 (43.6) 16 (64.0) 137 (42.3) 0.07 
Proteinuria - no. (%) 57 (16.3) 8 (32.0) 49 (15.1) 0.03 
Echocardiography data     
LV Ejection fraction  62.3 + 16.4 60.9 + 14.2 62.9 + 16.6 0.70 
Standard Electrocardiography     
Left ventricular hypertrophy - no. (%) 75 (21.5) 6 (24.0) 69 (21.5) 0.75 
History     
Heart failure - no. (%) 65 (18.6) 14 (56.0) 51 (15.7) <0.001 
Cause of heart failure – no. (%)   Ischemic 37 (57) 7 (50) 30 (59) 0.55 
                             Nonischemic 28 (43) 7 (50) 21 (41) 
Hypertension - no. (%) 242 (69.3) 21 (84.0) 221 (68.2) 0.10 
 Diabetes mellitus - no. (%) 87 (24.9) 3 (12.0) 84(25.9) 0.12 
 Angina pectoris - no. (%) 87 (24.9) 8 (32.0) 79 (24.4) 0.40 
  Previous myocardial infarction - no. (%) 32 (9.2) 2 (8.0) 30 (9.3) 0.83 
  Chronic kidney disease - no. (%) 138 (40.0) 14 (56.0) 124 (38.3) 0.08 
   Dyslipidemia - no. (%) 162 (46.4) 16 (64.0) 146 (45.0) 0.07 
   Hyperuricemia - no. (%) 61 (17.4) 8 (32.0) 53 (16.4) 0.047 
Transient ischemic attack – no. (%) 13 (3.7) 2 (8.0) 11 (3.4) 0.24 
Cerebral infarction – no. (%) 90 (25.8) 10 (40.0) 80 (24.7) 0.09 
Medications  
   
ACEI/ARB - no. (%) 137 (39.3) 10 (40.0) 127 (39.2) 0.94 
β blokers, no> (%)  174 (49.9) 13 (52.0) 161 (49.7) 0.82 
Calcium channel blockers - no. (%)   156 (44.7) 16 (64.0) 140 (43.2) 0.04 
Antiplatelet agents - no. (%) 139 (39.8) 9 (36.0) 130 (40.1) 0.68 
Statins - no. (%) 100 (28.7) 9 (36.0) 91 (28.0) 0.40 
Anti-diabeteic – no. (%) 63 (18.1) 1 (4.0)  62 (19.1) 0.06 
*Plus-minus values are mean + SD. P-value was established by using the Fisher’s exact test, t-test or Mann–Whitney U-test. Abbrevalation:  
 
Multivariable-adjusted ORs for Paf are shown in Table 2. The strong 
association between HF and Paf persisted after adjusting for age and 
proteinuria (OR was 5.40, 95% CI 2.07-14.1, p=0.0006), while neither 
the association between Paf and age nor the association between Paf 
and proteinuria were statistically significant after multivariable 
adjustment (p=0.40, p=0.66, respectively).   
 
 




Figure 1: Odds ratios (OR) and 95% confidence intervals (CI) of Paf 
The horizontal bars represent 95% confidence intervals. Date are adjusted for vrialbes showing the significant association by univariate regression analysis.
  
Table 2. Univariable and multivariable logistic regression for the association with Paf 
 
Variables Univariable Multivariable (Chi-square: 20.2)* 
  OR (95%CI) P value OR (95%CI) P value 
Age, per 1 year increment 1.03 (1.00-1.06) 0.03 1.01 (0.98-1.04) 0.40 
eGFR<60 mL/min/1.73m2, Yes vs. No 2.15 (0.92-5.03) 0.08   
Proteinuria, Yes vs. No 2.64 (1.08-6.45) 0.03 1.25 (0.46-3.37) 0.66 
Heart failure, Yes vs. No 6.81 (2.93-15.9) <0.0001 5.40 (2.07-14.1) 0.0006 
               *Data are adjusted for age, proteinuria and HF. 
 
Next, we evaluated the diagnostic accuracy of 4 selected risk factors to 
discriminate Paf group from Paf (-) group. Age per 1 year increment, 
proteinuria, and HF could distinguish Paf (+) patients from Paf (-) with 
AUC of 0.66, 0.58, and 0.70, respectively (Table 3). Notably, the value 
of AUC to predict Paf was significantly increased by the presence of HF 
(p<0.0001), in which sensitivity was 56% and specificity was 84%. These 
results suggest the importance of HF history to predict Paf.   
 
Table 3. Diagnostic accuracy 
 
 Variables AUC P value Sensitivity Specificity 
Age, per 1 year increment 0.66 0.01 76%* 53%* 
eGFR<60 mL/min/1.73m2, Yes vs. No 0.59 0.07 64% 55% 
Proteinuria, Yes vs. No 0.58 0.04 32% 85% 
Heart failure, Yes vs. No 0.70 <0.0001 56% 84% 




There have been few studies of the prevalence and the risk factors of 
Paf in patients with CVD who have many comorbidities contributing to 
the increased risk of AF. In the present study using 24-hour Holter ECG, 
we showed that Paf was detected in 25 patients (7.2%) of the 349 
patients with established CVD but without known AF, who visited 
outpatients department. In addition, we found that among many risk 
factors of AF so far identified in the epidemiological studies, HF was 
significantly associated with Paf, independent of other conventional 
risk factors in general and of proteinuria in particular.  
 
Coexistence of AF and HF has long been well acknowledged [1, 8, 20-23], 
and it is clear that AF confers the increased risk of developing HF, and 
HF predisposes to AF. However, it remains unclear whether HF is 
independently associated with Paf in the patients with CVD, who have 
multiple comorbidities such as advancing age, a history of myocardial 
infarction, valve disease, left ventricular dysfunction, hypertension, 
diabetes, and CKD. Given that each of these comorbidities contribute 
to increased risk of AF, the association between HF and Paf is likely to 
be confounded by these comorbidities. In our study, the prevalence of 
hypertension, diabetes, eGFR<60 was comparable between the 
patients with and without Paf. The multivariate regression analysis 
revealed that the association between Paf and HF remains significant 
after adjusting for age and proteinuria, which were significantly 
associated with Paf in univariate regression analysis. These findings 
may have important consequence for the management of HF patients.   
 
Several mechanisms may explain the increases risk of Paf in HF 
patients. Paf usually involves ectopic beats originating the cardiac 
muscle sleeve around pulmonary veins by rapid focal activity or local 
re-entry [24-27]. These ectopic firings mechanisms are promoted in HF, 
because HF prolongs the action potential duration (APD) and enhances 
Ca2+ uptake into sacroplasmic reticulum, which causes ectopic firing as 
well as early afterdepolarization (EAD) initiation [27]. A second possible 
mechanism may involve arterial cell Ca2+ overload and ryanodine 
receptors (RyR) dysfunction in HF [28]. These changes induce abnormal  
diastolic release of Ca2+ from sarcoplasmic reticulum, and induce 
transient inward current that underlie delayed after depolarization 
(DAD)-related AF[21]. Third, Paf may be caused by excessive activation 
of neurohumoral system including sympathetic nervous system and 
renin-angiotensin-aldosterone system (RAAS) in HF. Abnormal 
autonomic innervation has been described in AF in both animal model 
and in humans. By using immunocytochemical techniques, Chang et al 
demonstrated the increased sympathetic nerve densities, increased 
atrial nerve sprouting and heterogeneous sympathetic hyper-
innervation occur in canine model of AF produced by long-term, rapid 
right atrial pacing[29]. Nguyen et al showed that atrial sympathetic 
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nerve densities are significantly increased in patients with HF[30].Lastly, 
it has been well known that atrial substrate of AF is generated in HF[27]. 
The hemodynamic overload induces atrial remodeling characterized by 
interstitial fibrosis and pro-inflammatory activation with cellular 
hypertrophy, accelerated apoptosis, and abnormal myocytes Ca2+ 
handling[31, 32]. These pathophysiological changes can induce Paf-
susceptible atrial substrates.      
 
Study Limitations  
 
We acknowledge the limitation of our study. First, this study is 
subjected to selection bias and confounding because of a small single-
center study. Second limitation is that prevalent Paf was evaluated 
based on a single examination of 24-hour Holter ECG. Obviously, this 
may have caused an underestimation of the true prevalence of Paf. 
Third limitation is the use of dipstick to evaluate protein, which 
potentially causes measurement bias. In addition, only one 
measurement of a urine protein may have caused underestimation of 
the prevalence of proteinuria. Forth, the number of HF was small and 
causes of HF were heterogeneous, thus we cannot assess cause-
specific association between HF and Paf. Lastly, the number of Paf 
patients were low, which limited the number of predictors 
(explanatory variables) to be evaluated in the multivariable logistic 




This study showed that Paf is robustly associated with HF in CVD 
patients without known AF. This finding suggests that HF patients 
should be considered a very high risk for Paf and should be 
recommended for more careful observation for the potential 
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